Compass Therapeutics (CMPX) executive Lerner bought 10,000 shares for $5,900 at $0.59
Neil Lerner, Chief Accounting Officer at Compass Therapeutics Inc. (CMPX), reported an open-market purchase of 10,000 shares for $5,900 at $0.59 on November 17, 2026. This transaction increased his direct holdings to 430,000 shares. The filing provides details on the transaction, previous holdings, and footnotes regarding unvested restricted stock units.
Compass Therapeutics’ chief accounting officer Neil Lerner buys $5,900 in stock
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, purchased 10,000 shares of the company's common stock for $5,900 on November 17, 2026. This transaction occurred when the stock was near its 52-week low, and InvestingPro analysis suggests the stock is undervalued. The company recently faced an FDA recommendation for an additional trial for its drug tovecimig, leading to adjusted price targets from several financial analysts.
Form 4 Compass Therapeutics, Inc.: Neil Lerner (Chief Accounting Officer) For: 17 November
This article reports on a Form 4 filing for Compass Therapeutics, Inc., concerning Neil Lerner, the Chief Accounting Officer, for transactions made on November 17. Form 4 filings disclose changes in beneficial ownership of securities by a company's insiders. The filing indicates insider activity at Compass Therapeutics.
At $0.59 a share, Neil Lerner bought 10,000 shares of Compass Therapeutics (CMPX).
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, purchased 10,000 shares of common stock at $0.59 per share on November 17, 2026. This transaction increased his total holdings to 430,000 shares, which includes 62,500 unvested restricted stock units. The RSUs are subject to service-based vesting conditions, with the first installment vesting on January 2, 2027.
Compass Therapeutics appoints Sapna Mehtani as vice president and head of intellectual property
Compass Therapeutics has announced the appointment of Sapna Mehtani as vice president and head of intellectual property, strengthening its leadership in managing its IP portfolio. This appointment follows the company's recent presentation of results from its Phase 2/3 COMPANION 002 trial for advanced biliary tract cancer at ESMO 2026. The company continues to advance its pipeline and management team.
Compass Therapeutics, Inc. Stock 12‑Month Price Target Cut to $5.26, Implies 580% Upside
Compass Therapeutics, Inc. (CMPX) has seen its average 12-month price target cut slightly from $5.33 to $5.26 by 11 analysts, with forecasts ranging widely from $0.9 to $12 per share. Despite the cut, the updated target suggests a significant 580% potential upside based on the Nov. 13 closing price. The consensus rating for CMPX remains a "Buy" from 15 covering analysts.
Wedbush maintains Compass Therapeutics at Neutral, lowers price target to $0.90 from $1
Wedbush has reiterated its "Neutral" rating for Compass Therapeutics (CMPX) but reduced its price target from $1 to $0.90, representing a 10% decrease. This new price target implies a 7.5% upside from the stock's closing price of $0.84 on November 9th.
State Street reports 7.74M Compass Therapeutics (CMPX) shares, but voting power covers fewer.
State Street Corporation reported beneficial ownership of 7,737,938 shares, or 4.3% of Compass Therapeutics (CMPX) common stock, as of September 30, 2026. The filing indicates shared voting power over 7,587,678 shares and shared dispositive power over the full 7,737,938 shares, with no sole voting or dispositive power. The report identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as entities involved.
Compass Therapeutics, Inc. (CMPX) Misses Q3 EPS by 3c
Compass Therapeutics, Inc. (NASDAQ: CMPX) reported its Q3 earnings per share (EPS), which came in at ($0.16). This figure was $0.03 worse than the analyst estimate of ($0.13).
Cash and securities total $163M as Compass Therapeutics (CMPX) posts a wider Q3 loss.
Compass Therapeutics (CMPX) reported a wider net loss of $27.2 million in Q3 2026, compared to $14.3 million a year prior, with a nine-month net loss of $70.6 million. Despite this, the company holds $163 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2028. Key clinical updates include the COMPANION-002 study for tovecimig meeting its primary endpoint for overall response rate and progression-free survival, though the FDA recommended a survival benefit trial before BLA submission.
Compass Therapeutics Q3 Results: Loss widens 87.5% YoY to $(0.15) per share
Compass Therapeutics reported a third-quarter loss of $(0.15) per share, which missed the analyst consensus estimate of $(0.13) by 15.38%. This loss represents an 87.5% widening compared to the $(0.08) loss per share reported in the same quarter last year, indicating increased operational costs or cash burn. The company's stock has seen significant declines over the past year, with a -80.49% return.
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported a net loss of $27.2 million for Q3 2026, nearly double the previous year, primarily due to increased manufacturing and R&D costs for tovecimig. The FDA has recommended an additional survival study before the submission of a Biologics License Application (BLA) for tovecimig, which could delay approval. Despite this, the company's cash and marketable securities of $163 million are expected to fund operations into 2028.
Compass Therapeutics unveils novel PD-1 cleavage action of CTX-10726, boosting cancer treatment potential.
Compass Therapeutics has revealed new data for its bispecific antibody, CTX-10726, which uniquely cleaves PD-1 receptors on T cells, enhancing the immune response against tumors, particularly in VEGF-A-rich environments. Preclinical results suggest that combining CTX-10726 with CTX-471 could lead to more potent and durable cancer immunotherapy. A Phase 1 trial for CTX-10726 in advanced solid tumors is currently underway.
Compass Therapeutics presents new data on CTX-10726 bispecific antibody
Compass Therapeutics presented new preclinical data on its CTX-10726 bispecific antibody at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data highlights a novel mechanism where CTX-10726 facilitates the cleavage and removal of PD-1 receptors from T cells, dependent on the presence of VEGF-A, suggesting targeted activity within the tumor microenvironment. A Phase 1 study of CTX-10726 is currently underway for patients with advanced solid tumors in the post-checkpoint setting.
Lab tests show an experimental cancer drug strips an immune-cell receptor only when a blood-vessel growth signal is present.
Compass Therapeutics (CMPX) is presenting novel mechanism of action data for its experimental cancer drug CTX-10726 at the SITC 2026 Annual Meeting. Preclinical studies revealed that CTX-10726, a PD-1 x VEGF-A bispecific antibody, removes PD-1 receptors from T-cell surfaces only in the presence of VEGF-A, enhancing its potency approximately ten-fold. An ongoing Phase 1 dose-escalation study is enrolling patients with advanced solid tumors who have failed previous checkpoint treatments and standard therapies.
Compass Therapeutics Presents Novel Mechanism of Action
Compass Therapeutics presented data on the novel mechanism of action for its bispecific antibody, CTX-10726, at the SITC 2026 Annual Meeting. This antibody, designed to block both PD-1 and VEGF-A, uniquely causes VEGF-A-dependent cleavage of PD-1 receptors from T cells, converting them into PD-1 negative cells. Preclinical studies also showed enhanced anti-tumor activity when CTX-10726 was combined with Compass’s CD137 agonist, CTX-471, in checkpoint inhibitor-resistant models.
Compass Therapeutics | SCHEDULE 13G/A: Others
This article is a placeholder indicating that a SCHEDULE 13G/A filing related to Compass Therapeutics has been submitted. The content "Document" suggests the actual filing details would be accessed via a link or embedded document.
Compass Therapeutics (CMPX) Stock Price, Chart & Analysis
This article provides a detailed analysis of Compass Therapeutics (CMPX) stock, including its latest price of $0.75 as of November 3, 2026, and a market cap of $138.22M. It highlights that the company pays no dividends, has 0% revenue growth year-over-year last quarter, and maintains a strong balance sheet with $199.1M in net cash. The report also covers valuation metrics, growth prospects, debt status, and analyst forecasts, noting an expected earnings growth per share of +40.5% by analysts.
Compass Therapeutics | 8-K: Current report
This document is a current report filed by Compass Therapeutics on Form 8-K. The content simply indicates "Document", suggesting that the full report details would be contained within the attached official filing.
Compass Therapeutics, Inc. Estimates – NASDAQ:CMPX
This article from TradingView provides an overview of Compass Therapeutics, Inc. (NASDAQ: CMPX) financials, including actuals and analyst estimates for the income statement, balance sheet, cash flow, and valuation metrics. It highlights that the market was closed and no trades were made at the time of publication. The platform allows users to compare reported data with average, high, and low estimates and visualize trends.
Compass Therapeutics publishes tovecimig trial results in JCO
Compass Therapeutics, Inc. (NASDAQ:CMPX) announced the publication of results from its Phase 2/3 COMPANION-002 study in the Journal of Clinical Oncology. The study evaluated tovecimig combined with paclitaxel in patients with previously treated advanced biliary tract cancer, meeting its primary endpoint with an objective response rate of 18.0% versus 5.3% for paclitaxel alone. It also met the key secondary endpoint of progression-free survival, showing a 56% reduction in the risk of disease progression or death.
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
Compass Therapeutics (Nasdaq: CMPX) has announced the publication of positive Phase 2/3 COMPANION-002 study results for tovecimig in combination with paclitaxel for advanced biliary tract cancer in the Journal of Clinical Oncology, with an oral presentation at ESMO 2026. The study met its primary endpoint of overall response rate (ORR) and key secondary endpoint of progression-free survival (PFS), showing a 56% reduction in the risk of disease progression or death. A post hoc analysis of overall survival (OS) adjusted for crossover demonstrated an OS hazard ratio of 0.85, and the safety profile was consistent with previous studies.
Compass Therapeutics, Inc. (CMPX) Stock Price, News, Quote & History
This article provides a detailed overview of Compass Therapeutics, Inc. (CMPX), a clinical-stage oncology-focused biopharmaceutical company. It includes current stock performance, key financial metrics, company overview, recent news, and analyst ratings. The data highlights the company's focus on developing antibody-based therapeutics and its stock's performance against the S&P 500.
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics, Inc. announced it granted stock options to a new employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, vesting over four years. This inducement grant is part of the Company's 2025 Inducement Plan and is separate from its 2020 Stock Option and Incentive Plan.
Spotlight On October 2026's Standout Penny Stocks
This article identifies three standout "penny stocks" for October 2026: Compass Therapeutics (CMPX), Arq (ARQ), and Xunlei (XNET). Each company is analyzed based on its financial health, market capitalization, operations, recent performance, and future prospects, highlighting their potential for growth despite current unprofitability for two of them. The market context suggests a favorable environment for value-and-growth-oriented investments.
Spotlight On October 2026's Standout Penny Stocks
This article highlights three standout "penny stocks" for October 2026: Compass Therapeutics (CMPX), Arq (ARQ), and Xunlei (XNET). Despite being pre-revenue or unprofitable, these companies are identified for their financial health, growth potential, and strategic developments. The analysis uses Simply Wall St's financial health ratings, offering an overview of each company's market position, operational focus, and recent financial performance.
At $0.92 a share, Compass Therapeutics (CMPX) accounting chief buys 20,000 shares.
Neil Lerner, Chief Accounting Officer at Compass Therapeutics, purchased 20,000 shares of CMPX common stock at $0.92 per share on October 1, 2026. This direct purchase brings his total holdings to 420,000 shares, which includes 62,500 unvested restricted stock units. These RSUs are subject to service-based vesting, with the first installment set to vest on January 2, 2027.
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares By Investing.com
Neil Lerner, Chief Accounting Officer of Compass Therapeutics (NASDAQ:CMPX), purchased 20,000 shares of company stock for $18,400 at $0.92 per share. This transaction occurred on October 1, 2026, and increases his direct holdings to 420,000 shares, which includes unvested restricted stock units. The purchase happened as the stock is trading near its 52-week low, and comes amidst varying analyst outlooks following an FDA recommendation for an additional trial for tovecimig.
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, recently purchased 20,000 shares of the company's common stock for $18,400. This transaction occurred on October 1, 2026, when the stock was trading near its 52-week low and is considered undervalued by InvestingPro analysis. Lerner now directly holds 420,000 shares, including unvested restricted stock units.
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. as of October 2. The filing is presented without additional commentary or details in the brief news item. The stock symbol CMPX is mentioned with a -4.88% change.
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com
This article from Investing.com is a brief announcement regarding a Form 4 filing for Compass Therapeutics, Inc. on October 2nd. It does not provide further details but indicates the filing's date and the company concerned. The article also includes general market data and related news snippets.
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. (CMPX) on October 2. Form 4 filings are used to disclose transactions by company insiders. The article includes the stock symbol CMPX and its performance on the given day.
Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast
This article provides an analysis of Compass Therapeutics Inc. (CMPX) stock, including analyst ratings and financial forecasts. Based on 15 analysts, the average price target for CMPX is $5.909, suggesting a significant upside. The article also details EPS forecasts, with FY2026Q3 projected at -0.127.
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, recently purchased 2,500 shares of the company's common stock for $2,849, bringing his total beneficial ownership to 400,000 shares. This transaction occurred as the stock trades near its 52-week low, and InvestingPro analysis suggests the stock is undervalued with a fair value of $1.47. The company is also navigating FDA recommendations for an additional trial of its treatment tovecimig, which has led several analysts to adjust their price targets.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended a trial demonstrating a survival benefit for tovecimig in biliary tract cancer (BTC) before a Biologics License Application (BLA) submission. Despite this, Compass believes their Phase 2/3 COMPANION-002 study data, showing significant improvements in objective response rate (ORR) and progression-free survival (PFS), justifies a BLA submission without a new trial, especially given the urgent unmet medical need for BTC patients. The company plans further engagement with the FDA while preparing the BLA.
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, recently purchased 2,500 shares, increasing his total ownership to 400,000 shares. This transaction is part of a larger trend of insider buying at CMPX, with 3 buys and 0 sells over the past year, indicating a positive outlook from insiders. Additionally, GuruFocus data shows 4 gurus holding CMPX shares, with most adding to their positions, further suggesting confidence in the clinical-stage biopharmaceutical company despite the inherent risks of drug development.
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position
Neil Lerner, Chief Accounting Officer at Compass Therapeutics (CMPX), purchased 2,500 common shares at $1.14 each on September 24, 2026. This transaction increased his direct holdings to 400,000 shares, which includes 62,500 unvested restricted stock units set to vest annually starting January 2, 2027. The filing indicates a neutral sentiment and highlights the insider's long-term position in the company.
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About?
Compass Therapeutics, Inc. (CMPX) is drawing market attention after the FDA recommended an additional survival study for its tovecimig biologics application in biliary tract cancer. The article highlights that the market will focus on the company's execution, customer response, and how sector conditions and competitive pressures affect its operations following this development. Investors are advised to look for consistent delivery and operational evidence in future disclosures rather than just the initial announcement.
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. (CMPX) on September 25, 2026. The Form 4 is a document filed with the SEC to disclose changes in beneficial ownership of securities by a company's insiders. The article provides no further details about the content of the filing or the transaction itself.
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5
Wedbush has downgraded Compass Therapeutics (CMPX) from Outperform to Neutral and significantly reduced its price target from $5 to $1. Despite this downgrade, the stock currently holds an average rating of "buy" with a mean price target of $6.75 among analysts.
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics' shares plummeted after the FDA recommended a survival benefit trial for its cancer drug, tovecimig, before BLA submission, despite the company's prior successful Phase 2/3 trial data on objective response rate and progression-free survival. The FDA's stance creates uncertainty for the drug's approval timeline and has significantly impacted CMPX's stock price, pushing it to a new 52-week low. Technical analysis indicates the stock is in a "sell rallies" mode, trading well below its major moving averages.
Compass Therapeutics Shares Drop After Downgrade From Wedbush
Compass Therapeutics (CMPX) shares experienced a nearly 7% decline on Wednesday following a downgrade from Wedbush. The article indicates that access to the full details of this report requires a premium subscription.
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)
Compass Therapeutics (CMPX) was downgraded to Neutral from Outperform by Wedbush after the FDA recommended an additional study for its lead asset, tovecimig. The cancer drug developer's stock continued to trade lower following this news. The biotech company is based in Boston, Massachusetts.
The FDA recommended a trial to show patients live longer. Compass says its current study is enough.
The FDA has recommended that Compass Therapeutics conduct an additional trial demonstrating overall survival benefit before submitting a Biologics License Application (BLA) for its drug, tovecimig, in advanced biliary tract cancer. Compass Therapeutics believes its current Phase 2/3 COMPANION-002 study, which showed significant improvements in objective response rate and progression-free survival, is sufficient for BLA submission, especially given the urgent unmet medical need. The company plans further engagement with the FDA to discuss the path forward, despite the initial unexpected feedback.
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5
Wedbush has downgraded Compass Therapeutics (CMPX) from Outperform to Neutral and significantly cut its price target from $5 to $1. This downgrade comes after the FDA recommended a new trial for Tovecimig in biliary tract cancer, causing the company's shares to drop. Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for various diseases.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended an additional trial demonstrating a survival benefit for tovecimig in biliary tract cancer patients before a BLA submission. Despite this, Compass intends to proceed with BLA preparations, citing significant improvements in ORR and PFS from their COMPANION-002 study and the urgent unmet medical need. The company remains confident in tovecimig's potential, believing the existing data supports its clinical meaningfulness.
Compass vows to press on with FDA application despite new trial request
Compass Therapeutics plans to proceed with its biologics license application (BLA) for tovecimig in advanced biliary tract cancer, despite the FDA recommending an additional clinical trial to show a survival benefit. The company's Phase 2/3 COMPANION-002 trial met its primary endpoint of progression-free survival but not overall survival, leading to a nearly 30% drop in Compass shares. Compass remains confident in its data and intends to engage with the FDA to find a path forward for approval, noting precedents like Summit Therapeutics which filed a BLA after similar FDA recommendations.
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall
Compass Therapeutics' shares dropped over 38% pre-bell after the company announced that the FDA recommended a new trial for Tovecimig in biliary tract cancer. The article implies that this news was perceived negatively by the market, leading to a significant stock price decline. Full details of the FDA's recommendations and the company's response are behind a paywall.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended an additional trial to demonstrate a survival benefit for tovecimig in biliary tract cancer before a BLA submission. The company, however, believes that a new trial is not warranted given the positive data from the COMPANION-002 study and the urgent unmet medical need. Compass Therapeutics intends to continue engaging with the FDA while preparing its BLA submission, expressing confidence in tovecimig's clinically meaningful activity.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA recommended a survival benefit trial before a Biologics License Application (BLA) submission for tovecimig in biliary tract cancer (BTC). Despite this, Compass plans to further engage with the FDA and prepare a BLA, confident in the positive Phase 2/3 COMPANION-002 study results which showed significant improvements in objective response rate and progression-free survival. The company believes a new trial is not warranted given the urgent unmet medical need and existing data.